Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma. | Front Immunol | 2023 | 37234166 | PubTator, text mining | PubMed |
| METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma. | Cell Commun Signal | 2023 | 37231451 | PubTator, text mining | PubMed |
| The interplay between N6-methyladenosine and precancerous liver disease: molecular functions and mechanisms. | Discov Oncol | 2023 | 37227534 | PubTator, text mining | PubMed |
| The role of regulators of RNA m6A methylation in lung cancer. | Genes Dis | 2023 | 37223516 | PubTator, text mining | PubMed |
| Expression pattern analysis of m6A regulators reveals IGF2BP3 as a key modulator in osteoarthritis synovial macrophages. | J Transl Med | 2023 | 37217897 | PubTator, text mining | PubMed |
| Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. | Signal Transduct Target Ther | 2023 | 37217462 | PubTator, text mining | PubMed |
| Activation of the HNRNPA2B1/miR-93-5p/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner. | J Cancer | 2023 | 37215455 | PubTator, text mining | PubMed |
| Mechanisms of N6‑methyladenosine modification in tumor development and potential therapeutic strategies (Review). | Int J Oncol | 2023 | 37203412 | PubTator, text mining | PubMed |
| The potential regulatory role of RNA methylation in ovarian cancer. | RNA Biol | 2023 | 37194218 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer. | BMC Med Genomics | 2023 | 37194014 | PubTator, text mining | PubMed |
| Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer. | Diagnostics (Basel) | 2023 | 37189494 | PubTator, text mining | PubMed |
| Identification of a New m6A Regulator-Related Methylation Signature for Predicting the Prognosis and Immune Microenvironment of Patients with Pancreatic Cancer. | Mediators Inflamm | 2023 | 37181810 | PubTator, text mining | PubMed |
| ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma. | Transl Androl Urol | 2023 | 37181232 | PubTator, text mining | PubMed |
| Identification of m6A-related lncRNAs as prognostic signature within colon tumor immune microenvironment. | Cancer Rep (Hoboken) | 2023 | 37178411 | PubTator, text mining | PubMed |
| Molecular Mechanisms Underlying Pluripotency and Self-Renewal of Embryonic Stem Cells. | Int J Mol Sci | 2023 | 37176093 | PubTator, text mining | PubMed |
| GPX8 deficiency-induced oxidative stress reprogrammed m6A epitranscriptome of oral cancer cells. | Epigenetics | 2023 | 37170591 | PubTator, text mining | PubMed |
| The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma. | BMC Gastroenterol | 2023 | 37170222 | PubTator, text mining | PubMed |
| m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis. | Front Oncol | 2023 | 37152066 | PubTator, text mining | PubMed |
| Machine learning-based construction of a ferroptosis and necroptosis associated lncRNA signature for predicting prognosis and immunotherapy response in hepatocellular cancer. | Front Oncol | 2023 | 37152064 | PubTator, text mining | PubMed |
| RNA methylation pattern and immune microenvironment characteristics mediated by m6A regulator in ischemic stroke. | Front Genet | 2023 | 37139237 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=15